KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Prepaid Assets (2020 - 2025)

AbCellera Biologics (ABCL) has disclosed Prepaid Assets for 5 consecutive years, with $67.1 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Prepaid Assets rose 20.3% year-over-year to $67.1 million, compared with a TTM value of $67.1 million through Dec 2024, up 20.3%, and an annual FY2024 reading of $67.1 million, up 20.3% over the prior year.
  • Prepaid Assets was $67.1 million for Q4 2024 at AbCellera Biologics, up from $40.1 million in the prior quarter.
  • Across five years, Prepaid Assets topped out at $75.4 million in Q4 2022 and bottomed at $6.0 million in Q4 2020.
  • Average Prepaid Assets over 5 years is $45.6 million, with a median of $45.2 million recorded in 2022.
  • The sharpest move saw Prepaid Assets skyrocketed 255.9% in 2021, then fell 25.99% in 2023.
  • Year by year, Prepaid Assets stood at $6.0 million in 2020, then surged by 255.9% to $21.2 million in 2021, then skyrocketed by 254.93% to $75.4 million in 2022, then decreased by 25.99% to $55.8 million in 2023, then increased by 20.3% to $67.1 million in 2024.
  • Business Quant data shows Prepaid Assets for ABCL at $67.1 million in Q4 2024, $40.1 million in Q2 2024, and $55.8 million in Q4 2023.